Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a ...

Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic ...

Historically, the most common treatment for wet macular degeneration (wAMD) involved anti-vascular endothelial growth factor (VEGF) injections, such as Avastin, Lucentis, and Eylea. These drugs work ...

Dr. Jeffrey Whitman answers questions about macular degeneration and the newer treatments available to prevent permanent blindness.

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two treatments per year.

Certain medications can be used to treat macular degeneration, although almost all available medications are specifically for age-related macular degeneration.

SaveHealth provides an overview of common vision problems and their respective medications and treatments.